Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug ...

Biogen will pay City Therapeutics $46m, which includes $16m upfront and $30m investment for a convertible note.

Biogen (NASDAQ:BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ((RNAi)) therapies ...

Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build ...

Biogen and City Therapeutics have announced a partnership worth over $1bn to develop new RNAi therapies. The collaboration ...

Biogen Inc. (NASDAQ:BIIB)’s recent partnership with City Therapeutics, Inc. to develop RNAi therapies for central nervous ...

Biogen partners with City Therapeutics to develop select novel RNAi-based therapies: Cambridge, Massachusetts Thursday, May 29, 2025, 10:00 Hrs [IST] Biogen Inc, a leading biotech ...

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments.

Biogen and City Therapeutics, a privately held developer of RNA-based “trigger molecules,” announced a partnership to develop ...

Biogen Inc. and City Therapeutics, Inc. announced a strategic collaboration to develop novel RNA interference (RNAi) therapies targeting central nervous system diseases. City Therapeutics will ...

Biogen (NASDAQ:BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ((RNAi)) therapies targeting serious diseases. Under the agreement, City Therapeutics will use ...